OCUL:NAS (USA) Also trade in: Germany

Ocular Therapeutix Inc

$ 3.86 0.2 (5.46%)
Volume: 620,660 Avg Vol (1m): 506,691
Market Cap $: 165.35 Mil Enterprise Value $: 136.08 Mil
P/E (TTM): 0.00 P/B: 4.42
Earnings Power Value -16.97
Net Current Asset Value 0.46
Tangible Book 0.87
Projected FCF -8.48
Median P/S Value 5.66
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt 2.18
Equity-to-Asset 0.49
Debt-to-Equity 0.69
Debt-to-EBITDA -0.44
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.01
DISTRESS
GREY
SAFE
Beneish M-Score -2.40
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -1482.99%
WACC 16.01%

Profitability & Growth : 3/10

Current vs industry vs history
Operating Margin % -2970.75
Net Margin % -3013.97
ROE % -148.13
ROA % -86.70
ROC (Joel Greenblatt) % -559.30
3-Year Total Revenue Growth Rate 4.40
3-Year Total EBITDA Growth Rate -14.50
3-Year EPS w/o NRI Growth Rate 2.80

» OCUL's 30-Y Financials

Financials (Next Earnings Date: 2019-05-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:OCUL

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:BLCM NAS:CALA NAS:FBIO ASX:PNV NAS:CMRX AMEX:AMPE OTCPK:AXIM NAS:NERV OTCPK:ELOX ROCO:6575 NAS:MTEM NAS:VTL BOM:531349 LSE:IMM NAS:CDXC NAS:ATHX NAS:CASI MIL:MLM NAS:KIN NAS:ARDX
Traded in other countries 0OT.Germany
Address 15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, PTX-TP, and OTX-IVT. The ReSure product is commercially available.

Ratios

Current vs industry vs history
PB Ratio 4.42
PS Ratio 74.24
EV-to-EBIT -2.34
EV-to-EBITDA -2.42
EV-to-Revenue 68.40
Current Ratio 6.14
Quick Ratio 6.11
Days Inventory 111.62
Days Sales Outstanding 36.87
Days Payable 2.00

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -18.40

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.44
Price-to-Median-PS-Value 0.68
Earnings Yield (Joel Greenblatt) % -42.89

More Statistics

Revenue (TTM) (Mil) $ 1.99
EPS (TTM) $ -1.57
Beta 2.42
Volatility % 72.7
52-Week Range $ 3.46 - 8.28
Shares Outstanding (Mil) 42.84

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y